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HFE—A Novel Nonclassical Minireview
Class I Molecule that Is
Involved in Iron Metabolism
complexes. Such nontransferrin-bound iron (NTBI) is ca-
pable of mediating tissue damage by stimulating free
oxidizing radical formation and lipid peroxidation. This
NTBI undergoes rapid and efficient first-pass extraction
by the liver. While the TfR2-mediated pathway (dis-
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cussed below) could account for iron overload in theIsrael
liver of young patients, NTBI may contribute to hepatic†Unite´ di’Immunite´ Cellulaire Antivirale
iron loading in HH patients, particularly in late stagesInstitut Pasteur
of the disease (Adams et al., 2000). Recently, it was
75724 Paris Cedex 15 demonstrated that NTBI is present also in the serum of
France HH heterozygotes who apparently do not suffer from
the common HH symptoms and show normal transferrin
saturation. This finding indicates a possible role for NTBI
as a prooxidant factor that might be connected to theIntroduction
higher risk of cardiovascular events in some of theseIron is a trace element that is essential to life, since it
individuals.plays a crucial role in many biochemical and physiologi-
In diseases associated with iron overload, iron storagecal mechanisms. As a consequence, nature has devel-
in the reticuloendothelial system (mainly monocytes andoped an array of elaborate processes for the absorption,
macrophages) differs, depending on the cause of ironstorage, and transport of iron within the body, and a
accumulation. In secondary iron overload resulting fromhomeostatic balance between these mechanisms is in-
dyserythropoiesis, hemolysis, or multiple transfusions,dispensable to good health. Most of the genes encoding
macrophages are loaded with iron. In HH, however, veryproteins involved in iron metabolism are regulated on
little iron is seen in the reticuloendothelial system, al-the transcriptional and posttranscriptional levels by a
though the hepatocytes suffer from iron overload. Thecomplex regulatory element (iron-responsive element
low iron level in HH monocytes/macrophages is accom-[IRE]) that is present in the mRNA UTRs (untranslated
panied by a low intracellular level of ferritin and consis-regions) and binds iron-sensor binding factors (iron-
tently augmented IRP (iron-responsive protein) activityresponsive proteins [IRPs]). The regulation of these
(Cairo et al., 1997). Since macrophages are the majorgenes is described in other reviews (Klausner et al.,
source of plasma iron, a defect in iron metabolism in1993; De Silva et al., 1996; Richardson and Ponka, 1997).
these cells might be directly involved in HH progression.The present review describes a novel nonclassical class
The reduced iron pool in HH macrophages could resultI MHC gene that is mutated in Hereditary Hemochro-
from inappropriate release of iron, decreased iron up-matosis (HH), an iron overload disease, and its putative
take, or both. It was demonstrated (Fillet et al., 1989) thatconnection to the immune system.
early release of hemoglobin iron to plasma is abnormallyHH—The Characteristics of an Autosomal-Recessive
high in HH macrophages. However, Moura et al. (1998a)Iron Overload Disease
observed that both control and HH monocytes releasedHH is an autosomal-recessive disorder of iron metabo-
iron, in the forms of ferritin and hemoglobin, with thelism, common among populations of northwest Euro-
same relative rate but that HH monocytes released twice
pean ancestry, with a prevalence of 1/200–1/400 homo- as much iron in the form of nonprotein low–molecular
zygous individuals; the penetrance is variable, with weight iron complexes as did control monocytes. While
severely afflicted patients accumulating iron first in the this phenomenon cannot account alone for the low iron
transferrin pool and later in parenchymal tissue of many pool in the cells, it could, in part, explain the high trans-
organs, leading ultimately to multiorgan dysfunction, in- ferrin saturation and nontransferrin-bound iron level in
cluding diverse pathologies of the liver (cirrhosis), pan- HH. Lower iron uptake in HH macrophages might also
creas (diabetes), joints (arthritis), heart (myocardiac fi- stem from their reduced phagocytic capacity (Van As-
brosis), and hypophysis (hypogonadism). Liver damage, beck et al., 1984). According to recent data, antibody-
including hepatocellular carcinoma, is the major cause mediated phagocytosis of red blood cells and Staphylo-
of mortality in HH. The particular susceptibility of the coccus aureus was indeed reduced in HH macrophages
liver to damage by iron overload stems from the fact (Moura et al., 1998b). These observations could account
that hepatocytes are active in transferrin (Tf)-mediated for the low level of intracellular iron (derived from phago-
iron uptake via at least three individual pathways: a cytized erythrocytes) in HH macrophages, which might
classical transferrin receptor (TfR)-mediated pathway also lead to the increased susceptibility of HH patients
that is common to most cells, a recently described TfR2- to some bacterial infections.
mediated pathway (Fleming et al., 2000), and a receptor- Structural Analysis of the HFE Protein—
independent pathway (De Silva et al., 1996). The latter A Nonclassical Class I Protein
involves internalization of holotransferrin bound to low- Linkage disequilibrium between HH and certain HLA
affinity, nonspecific cell surface binding sites and inter- class I alleles, HLA-A3 and, to a lesser extent, HLA-
nalization of holotransferrin in the cellular fluid phase. A29, (Simon et al., 1976; Porto et al., 1998) and the
In HH patients, as transferrin becomes highly saturated, observation that b2m knockout mice suffer from iron
iron accumulates in the plasma in low–molecular weight overload (De Sousa et al., 1994) led to the positional
cloning of the HFE gene, which is telomeric to the classi-
cal HLA region on chromosome 6p (detailed in a review‡ To whom correspondence should be addressed (e-mail: rachele@
post.tau.ac.il). by Feder, 1999). Sequence analysis and the subsequent
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crystalization of the encoded protein revealed homology of the insulin receptor (Stagsted et al., 1990). Both HFE
and TfR undergo conformational changes following as-to MHC class I proteins (37% identity in the ectodomain).
About 80% of HH patients were found to be homozygous sociation, but the changes in TfR seem to be more dra-
matic. These changes might affect signaling via the TfRfor a single base transition in the HFE gene, resulting in
the substitution of tyrosine for cysteine at position 282 cytoplasmic tail or may influence TfR-facilitated release
of iron from endosomal Fe-Tf.(C282Y) of the unprocessed polypeptide. It was pre-
dicted that this mutation would prevent correct folding Since, so far, HFE does not appear to play a role in
antigen presentation, it is described as a nonclassicalof the a3 domain and, hence, assembly with b2m and
presentation on the cell surface. Subsequent studies MHC class I molecule. MHC class I molecules are capa-
ble of functions other than antigen presentation. Somehave confirmed this prediction. The gene encodes a
348 residue type I transmembrane glycoprotein, which have been shown to interact with receptors such as the
insulin or epidermal growth receptors (Schreiber et al.,associates with the class I light chain b2m and is mu-
tated in most patients with HH (reviewed by Drakesmith 1984; Fehlmann et al., 1985). Antibodies against these
MHC class I proteins reduce surface binding of insulin orand Townsend, 2000). In both HFE and classical class
I molecules, the a1-a2 superdomain forms a platform of epidermal growth factor to their respective receptors,
suggesting that these MHC class I proteins are involvedcomprising an eight-strand antiparallel b sheet topped
by two a helices, which is positioned on top of the in the formation of high-affinity ligand binding sites. The
nFcR is a nonclassical MHC class I molecule that actsIg constant–like domain a3 and b2m. Classical class I
molecules bind peptides in a prominent groove between as an antibody transporter (Ghetie and Ward, 1997). The
current model for nFcR function proposes binding of athe a1-a2 domain helices and interact with macromole-
cules such as T cell receptors and the T cell coreceptor ligand at acidic pH and transport in acidic vesicles
through the epithelial monolayer. Further evidence sug-CD8. On the other hand, HFE does not bind classical
class I binding peptides, and its crystal structure sug- gests the involvement of the nFcR in IgG homeostasis
in the serum. Like HFE, the rat nFcR structure revealedgests that the ancestral peptide binding groove is too
narrow for such a function. Emerging results suggest a fold similar in most respects to the standard MHC fold
but with a filled in or nonexistent groove (Burmeister etthat the functional role of HFE may lie in its interaction
with the TfR. In solution, HFE binds TfR tightly at pH 7 al., 1994). The binding cleft in nFcR is not used at all,
and the interaction with the Fc of IgG is transferred tobut not at pH 6, suggesting that HFE dissociates from
TfR in acidified compartments. Biochemical studies the side of the membrane-distal superdomain, formed
by the intimate association of the a1 and a2 domainsshowed that HFE and Fe-Tf can bind simultaneously to
TfR to form a ternary complex consisting of one Fe-Tf around its interface with b2m (Kim et al., 1999). The
combined data suggest that the nonclassical class Imolecule and one HFE molecule bound to a TfR homodi-
mer and that HFE inhibits the TfR-Tf interaction by bind- proteins are related and that the specific fold of their a1-
a2 domain helices might have served a unique functioning near or at the Tf binding site of TfR (Lebron and
Bjorkman, 1999). The crystal structure of a complex be- involving binding with specific membrane receptors.
Putative Connection between Iron Metabolism andtween the ectodomains of HFE and TfR (Bennet et al.,
2000) has a two-fold symmetry, revealing that a single the Immune System through the HFE Molecule
Many MHC class I–like (class Ib) molecules are endowedHFE molecule contacts each polypeptide chain of the
TfR homodimer. The relative orientations of both mole- with immunological functions. Some of them (e.g., Q7
and Q9) fix and present a diverse array of peptides tocules indicate that HFE and TfR associate on the same
membrane, rather than between opposing membranes. CD81 ab lymphocytes and, therefore, could theoretically
have a function similar to that of classical class Ia MHCIt is likely that changes in the TfR, rather than HFE,
mediate the pH-dependent HFE-TfR interaction. This molecules. However, most class I–like molecules have
evolved to perform different and more specific immuneassumption stems from the observation that neither the
individual HFE histidines (His-74 and His-150) nor the tasks for which they often interact with particular lym-
phocyte subsets (Braud et al., 1999). Human HLA-E andclustered His residues are in the interface with TfR. At
least one of the TfR histidines (His-475) is shifted and its mouse ortholog Qa1 preferentially present peptides
derived from leader sequences of molecules trans-forms a hydrogen bond with the partner His-475 across
the dimer interface, following complexation with HFE. ported into the ER and, more predominantly, those de-
rived from a conserved motif of MHC class Ia molecules,Consequently, HFE-induced structural changes might
influence the TfR-facilitated release of iron at acidic pH. through which they control the activation of a subset of
CD94/NKG21 NK cells. Others, like CD1d, preferentiallyThe distance between the a1 and a2 helices (the pep-
tide binding groove of classical class I molecules) is associate with lipids and interact with a restricted subset
of T lymphocytes known as NK/T cells, coexpressingcritical to the interaction of HFE with TfR. Thus, if the
HFE groove were open as the result of binding a peptide, NK cell markers with a very restricted set of TCRs (e.g.,
Va24 and Vb11 in humans). These cells, by secretingit would prevent the interaction between HFE and TfR
seen in cocrystals. The binding affinities for TfR of HFE large amounts of IL-4, are considered to be intimately
involved in the innate immune responses, which set upmutants, designed on the basis of the HFE crystal struc-
ture, allowed localization of the TfR binding site on HFE the conditions for the emergence of adaptative T cell
responses. The nFcR, without any bound material in itsto the C-terminal portion of the a1 domain helix and an
adjacent loop, a region distinct from the ligand binding closed a1a2 groove, interacts laterally with its ligand
and promotes maternal IgG gut absorption, transplacen-site of class I MHC and related proteins (CD1 and nFcR).
However, it may be similar to the site on class I MHC tal IgG transport, and IgG reabsorption from the initial
urine filtrate. It is, therefore, tempting to speculate thatthat is recognized by natural killer inhibitor receptors
(KIRs), a region that also involves residues on the C-ter- HFE, too, in addition to its regulatory role in iron metabo-
lism, could have preserved some immunological func-minal portion of the a1 domain helix. The a1 domain of
classical class I molecules is also involved in the binding tion. However, both the natural history of HH patients
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with a C282Y homozygous mutation (with no noticeable molecules (MIC A and B) expressed in the gut. Whether
immunodeficiency) and the analysis of HFE KO mice these lymphocytes also interact with HFE molecules
without any detectable gross alteration of their immune abundantly expressed in crypt cells remains to be estab-
system (Bahram et al., 1999) do not support the notion lished. Such an interaction could initiate gd T lymphocyte
that HFE molecules play a major immunological role. activation and cytokine secretion, thereby modulating
This, however, does not preclude that HFE molecules the fate (growth, apoptosis, or differentiation) of intesti-
have a more specific immune function. In fact, the ligand nal epithelial cells during their migration from the crypt
for specific T lymphocyte subsets that accumulate in toward the tip of the villus, where iron uptake takes
the gut of mammalian species is still unknown. HFE is place.
one of the possible candidates. In view of the many peculiarities of gut-associated
Even if HFE does not play a major immunological role, immunity (local differentiation of CD81 T lymphocytes
it is conceivable that the immune system is involved, expressing CD8aa homodimers, prominent accumula-
through HFE, in the control of iron metabolism. There tion of gd T lymphocytes selectively expressing g5d in
are, in fact, some indications supporting such a hypothe- mouse) and the gut-restricted expression of several
sis. In T lymphocytes, the TfR is associated with the MHC class I–like molecules (i.e., MIC, A, B, C1d, and
TCR z chain, one of the two subunits responsible for HFE), a cross-talk between gut-associated lymphocytes
the transduction of an activation signal following antigen and intestinal epithelial cells is conceivable. In such a
recognition. The TfR, through this interaction, copartici- process, HFE could play a central role and, conse-
pates in T cell activation (Salmeron et al., 1995). It is also quently, control iron absorption. Selective elimination of
known that the CD4/CD8 peripheral blood lymphocyte intraepithelial cells programmed for active iron plasma
(PBL) ratio is often high, due to a reduction in the number delivery is conceivable in the event of iron body over-
of CD81 T lymphocytes in most HH patients with liver load. As discussed above, gd T lymphocytes and/or
damage. A similar reduction in the number of CD81 T some subsets of intraepithelial CD81 ab T lymphocytes
lymphocytes was also documented in liver biopsies from could, coordinately, fulfill such a task.
HH patients (Porto et al., 1997). Alterations in CD4/CD8 The great variability of the clinical/histopathological
ratios were related to the clinical/histopathological sta- status of C282Y HH patients suggests that iron metabo-
tus of HH patients but not to the HFE mutation itself. lism control is a complex multifactorial process in which
These changes remain stable over time, even after cor- special effector cells of the immune system may be
rection of iron overload by intensive phlebotomy treat- involved.
ment. Thus, an HFE-independent cofactor of poor prog-
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